NewReferencesToProblem: verschil tussen versies
(→Uitvoering) |
(→Realisation) |
||
(6 tussenliggende versies door dezelfde gebruiker niet weergegeven) | |||
Regel 3: | Regel 3: | ||
Upon acceptance of the revision of the HCIM Problem, in release 2024 the HCIM Problem will disappear. This means that HCIMs currently referring to the HCIM Problem will have to be modified.<br> The HCIM Problem represented multiple concepts and these have been modelled in separate HCIMs after the revision of the HCIM Problem. | Upon acceptance of the revision of the HCIM Problem, in release 2024 the HCIM Problem will disappear. This means that HCIMs currently referring to the HCIM Problem will have to be modified.<br> The HCIM Problem represented multiple concepts and these have been modelled in separate HCIMs after the revision of the HCIM Problem. | ||
− | === | + | ===Realisation=== |
The following HCIMs are eligable to replace the reference to the HCIM Problem: | The following HCIMs are eligable to replace the reference to the HCIM Problem: | ||
*[[Condition-v1.0(2024EN) |Condition]] | *[[Condition-v1.0(2024EN) |Condition]] | ||
Regel 17: | Regel 17: | ||
|HCIM | |HCIM | ||
|Current reference | |Current reference | ||
− | | | + | |Replacement reference(s) |
|Old information model | |Old information model | ||
|New information model | |New information model | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
− | |width="20%" |[[ | + | |width="20%" |[[Admission-v2.0(2024EN)| Admission]] |
− | |width="20% | + | |width="20%" |[[Problem-v4.7(2024EN)|Problem]] |
− | |width="20%" |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[HypersensitivityIntolerance-v1.0(2024EN) | HypersensitivityIntolerance]] | + | |width="20%" |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[Reaction-v2.0(2024EN) | Reaction]]<br>[[Symptom-v1.0(2024EN) | Symptom]] |
+ | |style="text-align:center;" |[[Bestand:Admission-v2.0Model(2024EN).png | 150px |link=]]<br>[[Media:Admission-v2.0Model(2024EN).png | full-size]] | ||
+ | | | ||
+ | |-style="vertical-align: top;" | ||
+ | |[[AdvanceDirective-v4.3(2024EN)| AdvanceDirective]] | ||
+ | |[[Problem-v4.7(2024EN)|Problem]] | ||
+ | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]] | ||
+ | |style="text-align:center;" |[[Bestand:AdvanceDirective-v4.3Model(2024EN).png | 150px |link=]]<br>[[Media:AdvanceDirective-v4.3Model(2024EN).png | full-size]] | ||
+ | | | ||
+ | |-style="vertical-align: top;" | ||
+ | |[[Alert-v4.2(2024EN)| Alert]] | ||
+ | |[[Problem-v4.7(2024EN)|Problem]] | ||
+ | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[HypersensitivityIntolerance-v1.0(2024EN) | HypersensitivityIntolerance]] [[#Notes | <sup>1</sup>]] | ||
|style="text-align:center;" | [[Bestand:Alert-v4.2Model(2024EN).png | 150px |link=]]<br>[[Media:Alert-v4.2Model(2024EN).png | full-size]] | |style="text-align:center;" | [[Bestand:Alert-v4.2Model(2024EN).png | 150px |link=]]<br>[[Media:Alert-v4.2Model(2024EN).png | full-size]] | ||
| | | | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
− | |[[ | + | |[[CareAgreement-v1.1(2024EN)| CareAgreement]] |
+ | |[[Problem-v4.7(2024EN)|Problem]] | ||
+ | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]] | ||
+ | |style="text-align:center;" |[[Bestand:CareAgreement-v1.1Model(2024EN).png | 150px |link=]]<br>[[Media:CareAgreement-v1.1Model(2024EN).png | full-size]] | ||
+ | | | ||
+ | |-style="vertical-align: top;" | ||
+ | |[[CareTeam-v1.0.1(2024EN)| CareTeam]] | ||
|[[Problem-v4.7(2024EN)|Problem]] | |[[Problem-v4.7(2024EN)|Problem]] | ||
− | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight | + | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[Symptom-v1.0(2024EN) | Symptom]] |
− | |style="text-align:center;" | [[Bestand: | + | |style="text-align:center;" |[[Bestand:CareTeam-v1.0.1Model(2024EN).png | 150px |link=]]<br>[[Media:CareTeam-v1.0.1Model(2024EN).png | full-size]] |
− | | | + | | |
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
|[[Encounter-v6.0(2024EN)| Encounter]] | |[[Encounter-v6.0(2024EN)| Encounter]] | ||
Regel 37: | Regel 55: | ||
|[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[HypersensitivityIntolerance-v1.0(2024EN) | HypersensitivityIntolerance]]<br>[[Reaction-v2.0(2024EN) | Reaction]]<br>[[Symptom-v1.0(2024EN) | Symptom]] | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[HypersensitivityIntolerance-v1.0(2024EN) | HypersensitivityIntolerance]]<br>[[Reaction-v2.0(2024EN) | Reaction]]<br>[[Symptom-v1.0(2024EN) | Symptom]] | ||
|style="text-align:center;" |[[Bestand:Encounter-v6.0Model(2024EN).png | 150px |link=]]<br>[[Media:Encounter-v6.0Model(2024EN).png | full-size]] | |style="text-align:center;" |[[Bestand:Encounter-v6.0Model(2024EN).png | 150px |link=]]<br>[[Media:Encounter-v6.0Model(2024EN).png | full-size]] | ||
+ | | | ||
+ | |-style="vertical-align: top;" | ||
+ | |[[EpisodeOfCare-v1.0(2024EN)| EpisodeOfCare]] | ||
+ | |[[Problem-v4.7(2024EN)|Problem]] | ||
+ | |[[Condition-v1.0(2024EN) | Condition]] [[#Notes | <sup>2</sup>]] | ||
+ | |style="text-align:center;" |[[Bestand:EpisodeOfCare-v1.0Model(2024EN).png | 150px |link=]]<br>[[Media:EpisodeOfCare-v1.0Model(2024EN).png | full-size]] | ||
| | | | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
Regel 45: | Regel 69: | ||
| | | | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
− | |[[ | + | |[[MedicalDevice-v4.0(2024EN)| MedicalDevice]] |
|[[Problem-v4.7(2024EN)|Problem]] | |[[Problem-v4.7(2024EN)|Problem]] | ||
|[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]] | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]] | ||
− | |style="text-align:center;" |[[Bestand: | + | |style="text-align:center;" |[[Bestand:MedicalDevice-v4.0Model(2024EN).png | 150px |link=]]<br>[[Media:MedicalDevice-v4.0Model(2024EN).png | full-size]] |
| | | | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
Regel 55: | Regel 79: | ||
|[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[HypersensitivityIntolerance-v1.0(2024EN) | HypersensitivityIntolerance]]<br>[[Reaction-v2.0(2024EN) | Reaction]]<br>[[Symptom-v1.0(2024EN) | Symptom]] | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[HypersensitivityIntolerance-v1.0(2024EN) | HypersensitivityIntolerance]]<br>[[Reaction-v2.0(2024EN) | Reaction]]<br>[[Symptom-v1.0(2024EN) | Symptom]] | ||
|style="text-align:center;" |[[Bestand:MedicationAgreement-v3.0Model(2024EN).png | 150px |link=]]<br>[[Media:MedicationAgreement-v3.0Model(2024EN).png | full-size]] | |style="text-align:center;" |[[Bestand:MedicationAgreement-v3.0Model(2024EN).png | 150px |link=]]<br>[[Media:MedicationAgreement-v3.0Model(2024EN).png | full-size]] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
Regel 73: | Regel 85: | ||
|[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[Symptom-v1.0(2024EN) | Symptom]] | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[Symptom-v1.0(2024EN) | Symptom]] | ||
|style="text-align:center;" |[[Bestand:MultidisciplinaryTeamMeeting-v2.0Model(2024EN).png | 150px |link=]]<br>[[Media:MultidisciplinaryTeamMeeting-v2.0Model(2024EN).png | full-size]] | |style="text-align:center;" |[[Bestand:MultidisciplinaryTeamMeeting-v2.0Model(2024EN).png | 150px |link=]]<br>[[Media:MultidisciplinaryTeamMeeting-v2.0Model(2024EN).png | full-size]] | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
Regel 99: | Regel 105: | ||
| | | | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
− | |[[ | + | |[[Signaling-v2.0(2024EN)| Signaling]] |
|[[Problem-v4.7(2024EN)|Problem]] | |[[Problem-v4.7(2024EN)|Problem]] | ||
|[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]] | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]] | ||
− | |style="text-align:center;" |[[Bestand: | + | |style="text-align:center;" |[[Bestand:Signaling-v2.0Model(2024EN).png | 150px |link=]]<br>[[Media:Signaling-v2.0Model(2024EN).png | full-size]] |
| | | | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
− | |[[ | + | |[[SkinDisorder-v3.4(2024EN)| SkinDisorder]] |
|[[Problem-v4.7(2024EN)|Problem]] | |[[Problem-v4.7(2024EN)|Problem]] | ||
|[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]] | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]] | ||
− | |style="text-align:center;" |[[Bestand: | + | |style="text-align:center;" |[[Bestand:SkinDisorder-v3.4Model(2024EN).png | 150px |link=]]<br>[[Media:SkinDisorder-v3.4Model(2024EN).png | full-size]] |
| | | | ||
|-style="vertical-align: top;" | |-style="vertical-align: top;" | ||
− | |[[ | + | |[[TreatmentObjective-v3.2.1(2024EN)| TreatmentObjective]] |
|[[Problem-v4.7(2024EN)|Problem]] | |[[Problem-v4.7(2024EN)|Problem]] | ||
− | |[[ | + | |[[DiagnosticInsight-v1.0(2024EN) | DiagnosticInsight]]<br>[[HypersensitivityIntolerance-v1.0(2024EN) | HypersensitivityIntolerance]]<br>[[Symptom-v1.0(2024EN) | Symptom]] |
− | + | |style="text-align:center;" | [[Bestand:TreatmentObjective-v3.2.1Model(2024EN).png | 150px |link=]]<br>[[Media:TreatmentObjective-v3.2.1Model(2024EN).png | full-size]] | |
− | | | + | |style="text-align:center;" | [[Bestand:TreatmentObjective_Nieuw(2024EN).png | 150px |link=]]<br>[[Media:TreatmentObjective_Nieuw(2024EN).png | full-size]] |
− | |||
− | |[[ | ||
− | |||
− | | | ||
− | |style="text-align:center;" |[[Bestand: | ||
− | |||
|} | |} | ||
+ | |||
+ | ===Notes=== | ||
+ | <sup>1</sup> HypersensitivityIntolerance reference should only be used when it is not medication related, as that is what the HCIM SurveillanceDecision is intended for.<br> | ||
+ | <sup>2</sup> An EpisodeOfCare relates to a condition that a health professional is following. |
Versie van 28 jun 2024 om 21:23
Reason
Upon acceptance of the revision of the HCIM Problem, in release 2024 the HCIM Problem will disappear. This means that HCIMs currently referring to the HCIM Problem will have to be modified.
The HCIM Problem represented multiple concepts and these have been modelled in separate HCIMs after the revision of the HCIM Problem.
Realisation
The following HCIMs are eligable to replace the reference to the HCIM Problem:
Depending on the nature of the concept of a HCIM currently referring to Problem, replacing the reference to the HCIM Problem requires a reference to one or more of the above HCIMs.
The table below shows, for each HCIM with a current reference to the HCIM Problem, which reference(s) will replace it.
Notes
1 HypersensitivityIntolerance reference should only be used when it is not medication related, as that is what the HCIM SurveillanceDecision is intended for.
2 An EpisodeOfCare relates to a condition that a health professional is following.